CurrentBlue Cross Blue Shield - IowaPolicy N/A

Dopamine Transporter Single-Photon Emission Computed Tomography of the Brain

Policy governs use of DaT‑SPECT imaging (ioflupane and other DaT ligands) to assist in differentiating parkinsonian syndromes from nonparkinsonian tremor and dementia with Lewy bodies from Alzheimer disease, and addresses investigational use for other mental/behavioral/neurodevelopmental conditions. Applies to Wellmark/Blue Cross Blue Shield - Iowa determinations of medical necessity.

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyDopamine Transporter Single-Photon Emission Computed Tomography of the Brain

Policy CodePolicy N/A

Change TypeAnnual review / renewal (no material changes)

Effective DateFebruary 2019

Next Review DateN/A

Key ActionObtain and document specialist (neurologist/movement disorder) evaluation confirming diagnostic uncertainty and how imaging will change management before ordering DaT‑SPECT.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Dec 2025Most recent literature update

2Primary clinical indications discussed

3–20%SWEDD proportion in PD studies

NoneProspective blinded studies vs criterion standard

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Policy history range

Coverage Criteria for DaT‑SPECT

Medically Necessary

Covered when one of the following clinical indications is met:

Medically necessary indications: Clinically uncertain dementia with Lewy bodies

DaT-SPECT may be considered medically necessary for individuals with clinically uncertain DLB.

Medically necessary indications: Clinically uncertain Parkinson disease

DaT-SPECT may be considered medically necessary for individuals with clinically uncertain PD.

Investigational

Not covered / investigational when ALL of the following are true:

Investigational uses: Criteria for clinically uncertain Parkinson disease or clinically uncertain dementia with Lewy bodies are not met

Use of DaT-SPECT in these circumstances is considered investigational because evidence is insufficient to demonstrate improved net health outcomes.

Investigational uses: Use is for other mental, behavioral, or neurodevelopmental conditions (e.g., ADHD, autism, alcohol dependence, OCD, PTSD) or for Alzheimer disease diagnosis/management

Evidence does not support improved diagnosis or management for these indications.

Appropriate use for diagnostic differentiation

Covered when ALL of the following are met

Clinical uncertainty: Diagnosis of essential tremor versus a parkinsonian syndrome remains unclear after appropriate clinical evaluation

Clinical evaluation includes history and physical examination using accepted criteria (IPMDS/MDS); uncertainty persists despite specialist assessment or observation over time.

Intended use: DaT-SPECT is requested as an adjunct to guide management decisions (for example, to avoid or reduce unnecessary dopaminergic therapy)

Imaging must be intended to inform a specific management decision rather than solely for diagnostic curiosity; not intended for routine AD diagnosis per policy.

Population: Adult individuals in whom the differential includes a neurodegenerative presynaptic parkinsonian syndrome (e.g., PD) versus a non-neurodegenerative cause (e.g., essential tremor, drug-induced or vascular parkinsonism)

Particularly appropriate when patients suspected of ET develop signs suggestive of PD and clinical differentiation remains uncertain.

Populations for Consideration

Potential patient populations for DaT‑SPECT consideration:

Population 1: Patients with dementia who have 2 or more core clinical features of dementia with Lewy bodies (probable DLB)

These patients meet criteria for probable DLB without DaT-SPECT and are not the target population for testing.

Population 2: Patients with dementia who have only 1 core clinical feature

Distinguishing between possible and probable DLB in these patients is unlikely to change management and is not the primary population of interest.

Population 3: Patients with dementia who have no core clinical features but one or more suggestive features

Primary population of interest for DaT‑SPECT to aid diagnosis of possible DLB when specialist assessment leaves uncertainty.

Evidence and Coverage Implications

Evidence summary and implications for coverage:

RCT evidence: A randomized trial (Kupsch et al) comparing DaT‑SPECT to no imaging showed no improvement in quality of life at 3 months or 1 year

Although imaging changed diagnosis/management in some studies, direct evidence of improved health outcomes was not demonstrated in the RCT.

Observational evidence: Observational studies and a meta-analysis reported changes in management (pooled ~54% change) following DaT‑SPECT

These management changes were not linked to demonstrated improvements in patient health outcomes; chain of evidence is incomplete.

Diagnostic validity limitations: Studies have methodological limitations (unclear selection, incomplete follow-up, inconsistent blinding) and limited postmortem reference‑standard data

Because of these limitations, diagnostic accuracy and resulting clinical utility cannot be definitively established from current studies.

Coverage stance by clinical indication

Coverage considerations based on available evidence and clinical input

Clinically uncertain Parkinson disease: Clinical input indicates DaT‑SPECT can be useful when a negative result is used to inform treatment decisions by reducing or avoiding unnecessary dopaminergic therapy

RCT evidence did not show QoL benefit at 1 year but clinical respondents note that follow-up may be too short to detect benefits in a slowly progressive disease.

Clinically uncertain dementia with Lewy bodies: Evidence is limited: few postmortem‑reference studies exist and none included the primary target population (patients with only suggestive features), so clinical validity and linkage to outcomes are not established

Clinical input supports potential utility when a positive scan would avoid harmful neuroleptic use, but direct outcomes data are lacking.

Other mental/behavioral/neurodevelopmental disorders: No studies demonstrate improved diagnosis or management for conditions such as ADHD, autism, OCD, PTSD, or substance use disorders

DaT‑SPECT is not supported for these indications based on available evidence.

Supported clinical indications

Statements from clinical input and professional guidelines supporting use of DaT-SPECT in specific uncertain diagnostic scenarios.

Clinically uncertain Parkinson disease: Clinical input and guideline statements indicate DaT‑SPECT is clinically useful when a negative result informs a decision to reduce or avoid dopaminergic therapy

Supported by clinical respondents and by guideline guidance noting usefulness for differentiating ET from presynaptic parkinsonian syndromes.

Clinically uncertain dementia with Lewy bodies: Clinical input and DLB guidance indicate DaT‑SPECT is clinically useful when a positive result would lead to avoidance of neuroleptics and alter management

DLB consortium and NICE guideline statements list reduced DaT uptake as an indicative biomarker to support diagnosis when uncertain.

Differential diagnosis of tremor/parkinsonism: Professional society guidelines support presynaptic dopaminergic imaging to differentiate essential tremor from presynaptic degenerative parkinsonian syndromes and to distinguish presynaptic from non‑presynaptic causes (but cannot reliably separate among degenerative parkinsonian syndromes)

Initial diagnostic use in clinically uncertain parkinsonism or DLB

Covered when ALL of the following are met

Primary criteria: 1) Diagnostic uncertainty exists between a neurodegenerative presynaptic parkinsonian syndrome (e.g., PD, PSP, MSA, DLB) and a non‑neurodegenerative cause (e.g., essential tremor, drug‑induced or vascular parkinsonism) OR uncertainty distinguishing DLB from Alzheimer's disease; 2) A neurologist or movement disorders specialist has evaluated the patient and documented the differential diagnosis and how imaging results would change management (for example, decisions about empiric dopaminergic therapy or avoidance of neuroleptics); 3) Imaging is intended to assess presynaptic dopaminergic deficit to inform diagnosis and management

Selection should target patients in whom imaging results would alter management; DaT‑SPECT is not a lone diagnostic test for PD and should follow specialist clinical assessment.

Clinical utility and diagnostic rationale

Clinical indications and rationale summarized from expert responses and literature citations

Use-case: Clinically uncertain parkinsonian syndromes: DaT‑SPECT (I‑123 FP‑CIT / ioflupane) is useful to assess nigrostriatal dopaminergic integrity to distinguish degenerative Parkinson disease/DLB from non‑degenerative causes such as essential tremor

Multiple studies and cost‑effectiveness analyses support diagnostic validity in uncertain cases though postmortem reference data are limited.

Avoid empiric treatment without confirmation: Empiric dopaminergic treatment in patients who do not have PD exposes them to unnecessary side effects; imaging can prevent inappropriate treatment and related harms

Expert rationale emphasizes risks (sedation, hallucinations, agitation) and that imaging may reduce unnecessary medication exposure.

Reference standard for diagnostic performance: Clinical diagnosis by a movement disorders specialist with 3–5 years follow‑up is used as a practical reference standard for evaluating DaT‑SPECT diagnostic accuracy3-5 years

Use of DaT‑SPECT for the diagnosis, management, or surveillance of Alzheimer disease is explicitly out of scope for this policy.

Regulatory and policy context notes that DaTscan approval and subsequent guidance do not extend to Alzheimer disease; the policy therefore considers DaT‑SPECT for Alzheimer disease to be out of scope for coverage determinations.

Patients who already meet criteria for probable dementia with Lewy bodies (i.e., two or more core clinical features) do not have diagnostic uncertainty and are not appropriate targets for DaT‑SPECT to resolve diagnosis.

No studies were identified that demonstrate DaT‑SPECT improves diagnosis or management for conditions such as ADHD, autism, alcohol dependence, obsessive‑compulsive disorder, or post‑traumatic stress disorder, and the policy considers these uses unsupported by evidence.

DaT‑SPECT can distinguish presynaptic dopaminergic deficit from non‑degenerative causes of parkinsonism but does not reliably differentiate Parkinson disease from other atypical parkinsonian syndromes (e.g., PSP, MSA).

The supplemental material did not enumerate every possible exclusion; clinical input focused on use in clinically uncertain Parkinson disease and clinically uncertain DLB rather than listing exhaustive non‑covered indications.

DaT‑SPECT is not a standalone diagnostic test for Parkinson disease; it should be performed only after a neurologist has established clinical suspicion and documented a differential diagnosis that includes neurodegenerative parkinsonian syndromes.

DaTscan is not indicated to guide routine empiric therapy for patients who already meet clear clinical criteria for Parkinson disease; treatment decisions for clinically diagnosed PD remain clinical judgments.

DaT‑SPECT use for other mental, behavioral, and neurodevelopmental disorders (and for Alzheimer disease management) is considered investigational due to insufficient evidence of clinical benefit.

A key limitation of the evidence base is the absence of prospective, independent, blinded studies comparing DaT‑SPECT with a criterion standard in patients with clinically uncertain Parkinson disease.

Use of DaT‑SPECT to improve patient health outcomes has not been demonstrated; a randomized trial found no improvement in quality of life at 3 months or 1 year for patients randomized to imaging versus no imaging.

Given the lack of evidence for behavioral, mental health, and neurodevelopmental indications, DaT‑SPECT is considered not medically necessary for these other conditions.

The supplemental documentation did not explicitly label certain items as not medically necessary; rather, clinical input was targeted to the diagnostic contexts of interest (clinically uncertain PD and DLB).

Routine use of DaT‑SPECT without a documented evaluation by a neurologist (or movement disorders specialist) is not supported; the record should document specialist assessment and that diagnostic uncertainty remains.

DaT‑SPECT is not intended for patients without clinical uncertainty and should not be used merely to justify empiric initiation of Parkinson disease therapy in cases where the diagnosis is already clear.

Regulatory and Coding References

Regulatory/Coding referencesmixed

FDA product code: KPS

DaTscan regulatory product code

Regulatory identifiermixed

FDA product code: KPS

FDA product code for DaTscan

Referenced radiopharmaceuticals / agentsmixed

123I-FP-CIT

Radiotracer (I-123 FP-CIT) used for DaT-SPECT (also referred to as ioflupane or DaTscan)

Covered CPT Codes (listed)CPT

78803

Radiopharmaceutical localization of tumor, inflammatory process or distribution of radiopharmaceutical agent(s) (includes vascular flow and blood pool imaging, when performed); tomographic (SPECT), single area (e.g., head, neck, chest, pelvis), single day imaging.

Coding remarksmixed

CPT®	registered trademark reference; no specific CPT codes listed in these chunks

Provider Action Items and Prior Authorization Guidance

Prior Authorization

Prior Approval and Benefit Verification

Prior approval — Not applicable. Providers should verify member benefits and coding details before ordering; CPT 78803 is commonly used for DaT‑SPECT reporting and improper coding or omission may result in claim processing issues.

Prior approval: Not applicable
Verify member benefits and applicable CPT/HCPCS/ICD coding prior to authorization (CPT 78803 referenced)

Prior Authorization

Prior Authorization Expectations and Indication

Prior authorization is expected when DaT‑SPECT is requested as a diagnostic adjunct to resolve clinical uncertainty between essential tremor and parkinsonian syndromes or between Alzheimer disease and dementia with Lewy bodies. Requests should document that diagnostic uncertainty persists after clinical evaluation by an appropriate specialist (neurologist or dementia specialist) and that imaging is intended to be adjunctive to, not a substitute for, clinical assessment.

Document that ET vs PD or AD vs DLB remains unclear after clinical evaluation by a neurologist or dementia specialist

Background and Evidence Context

Background: Parkinsonian syndromes are characterized by bradykinesia, rigidity, resting tremor, and gait disturbance; Parkinson disease is the most common cause, and dementia with Lewy bodies commonly presents with parkinsonism plus cognitive and neuropsychiatric features.

Evidence and Coverage Implications (supporting evidence context)

Evidence and Coverage Implications (supporting evidence context):

RCT and observational evidence: Available RCT evidence did not demonstrate improved quality of life at 3 months or 1 year; observational studies report frequent changes in diagnosis/management but lack linked outcome benefits

This supporting context underscores the limited direct evidence of health‑outcome improvement despite management changes.

Methodological limitations: Many diagnostic studies have limitations including inconsistent blinding, selection bias, and incomplete follow‑up, reducing confidence in accuracy estimates

These limitations prevent construction of a definitive chain of evidence from test performance to improved patient outcomes.

Definitions and Key Terms

DaT ligand examples — examples of ligands and injection-to-scan timing

Examples of DaT ligandsIodine-123 β-CIT (123I-β-CIT); 123I-FP-CIT (ioflupane, DaTscan); 99mTc-TRODAT-1.

Injection-to-scan timing: 123I-β-CITRequires ~24 hours delay between injection and scan.

Injection-to-scan timing: 123I-FP-CIT (DaTscan)Can be injected 3–6 hours before the scan.

Other notes on ligandsSome ligands (eg, 123I-β-CIT, 123I-FP-CIT) may also bind serotonin transporter to varying degrees; choice affects timing and selectivity.

Scans without evidence of dopaminergic deficit (SWEDD) — prevalence notes

Definition of SWEDDScans Without Evidence of Dopaminergic Deficit (SWEDD) are cases where individuals clinically diagnosed with PD or DLB have normal DaT-SPECT scans.

Policy Revision History

December 2025policy_reviewLatest

Annual review and policy renewal performed (policy history indicates annual reviews and revisions through 2025).

December 2024policy_review

Annual review performed (policy history entry for December 2024).

February 2019effective_date

Policy Summary

PayerBlue Cross Blue Shield - Iowa

PolicyDopamine Transporter Single-Photon Emission Computed Tomography of the Brain

Policy CodePolicy N/A

Change TypeAnnual review / renewal (no material changes)

Effective DateFebruary 2019

Next Review DateN/A

Key ActionObtain and document specialist (neurologist/movement disorder) evaluation confirming diagnostic uncertainty and how imaging will change management before ordering DaT‑SPECT.

SourceLink

On This Page

Supported by SNMMI/EANM practice guidelines and MDS statements.

Cited meta‑analytic and validation literature use specialist clinical follow‑up as an accepted reference standard when postmortem data are unavailable.

State the intended adjunctive use and how results will inform management decisions

Prior Authorization

Scope of Covered Indications and Investigational Uses

Prior authorization guidance — approval is generally limited to patients meeting the evidence‑based selection criteria (clinically uncertain PD or clinically uncertain DLB populations). DaT‑SPECT is investigational when criteria are not met or when requested for other mental, behavioral, or neurodevelopmental conditions.

Covered indication: clinically uncertain PD (ET vs parkinsonian syndromes) or clinically uncertain DLB after specialist assessment
Not covered/investigational: uses outside these indications (including behavioral health diagnoses)

Documentation Required

Required Clinical Evaluation and Supporting Documentation

Clinical documentation required — include neurologist or dementia‑specialist evaluation, description of clinical features and duration, documentation of diagnostic uncertainty after observation and examination, prior treatments tried or considered, and a statement whether the patient would otherwise receive empiric therapy without imaging.

Clinical note from specialist documenting uncertainty between ET and parkinsonian syndrome or between AD and DLB
Duration of symptoms and relevant exam findings (eg, core/suggestive DLB features; parkinsonism signs)
Note whether empiric dopaminergic therapy or neuroleptic therapy would be started absent imaging

Note

Evidence Standards and Study‑Design Limitations (Informational)

Evidence and study‑design considerations that may affect authorization — methodologically credible studies report patient selection criteria, clinical characteristics, a suitable reference standard (postmortem neuropathology preferred or clinical diagnosis with adequate follow‑up), and blinded interpretation. Studies using clinical diagnosis alone as the reference standard have important limitations and provide limited evidence of improved accuracy.

Preference for studies with postmortem neuropathologic reference standard or ≥3 years clinical follow‑up
Document if cited evidence relies on clinical diagnosis as reference standard (acknowledge limitations)
Note potential bias from lack of blinding, selection issues, and incomplete follow‑up

Documentation Required

Interpretation Standards and Site Reference Calibration

Interpretation and site calibration — visual interpretation is usually sufficient, but sites performing semiquantitative analysis should establish reference ranges via healthy controls or calibrate with a reference database. Specify whether interpretation will be visual, quantitative, or combined.

State method of interpretation (visual vs semiquantitative)
If semiquantitative, document site reference range or calibration approach

Note

Clinical Management, Empiric Treatment vs Imaging, and Observation

Clinical management impact and risk considerations — imaging results must be tied to management decisions (eg, avoiding or reducing dopaminergic therapy when scan is normal; avoiding neuroleptics when scan is positive for DLB). Consider clinical observation first; document rationale for imaging versus active surveillance or empiric treatment given risks of empiric therapy.

Explain how DaT‑SPECT result will change therapy (reduce/avoid dopaminergic agents or neuroleptics)
If observation was considered, document why imaging is preferred to delayed treatment or watchful waiting
Identify patients who would be empirically treated without imaging and rationale for requesting scan instead

Billing Rule

Coding and Documentation Requirements

Coding and billing guidance — report provider services using appropriate CPT/HCPCS/Revenue/ICD codes. CPT 78803 is referenced for SPECT single area imaging. Improper coding may cause claim issues or denials.

Include appropriate ICD diagnosis supporting the test indication
Use CPT 78803 for SPECT when applicable and ensure ancillary radiopharmaceutical codes as required

Note

Population Triage and Pre‑Imaging Evaluation

Population triage and utilization — primary candidates are patients with dementia who have suggestive features but lack core DLB features, and patients with tremor where ET vs parkinsonian syndrome remains unclear after specialist assessment. Consider specialty referral and observation over time before imaging when clinically appropriate.

Primary DLB target: dementia with suggestive features but insufficient core features
Primary PD target: suspected ET who develop signs suggestive of PD where uncertainty persists after evaluation
Consider referral to movement‑disorder specialist when available

Documentation Required

Supporting Evidence and Safety Information for Authorization

Supporting evidence documentation — include citations or summaries of the evidence used to justify the request and note safety data (eg, DaTscan safety analyses). Provide chain‑of‑evidence statements when direct outcome data are limited.

Attach relevant publications or summarize key evidence that supports clinical utility for the patient
Note known safety profile and references when relevant

Prevalence in PD studiesReported proportion in PD studies ranges from about 3% to 20%.

Prevalence in DLB studyApproximately 10% of clinically diagnosed DLB patients had normal DaT-SPECT in one study referenced.

DaTscan / DaT‑SPECT definition

Basic definitionDaTscan / DaT‑SPECT: single‑photon emission computed tomography imaging for visualization of striatal dopamine transporter binding to assist evaluation of suspected parkinsonian syndromes.

Intended use per FDAIndicated to assist in evaluation of adult individuals with suspected parkinsonian syndromes and to help differentiate essential tremor from parkinsonian tremor; adjunct to other evaluations.

Modalities of analysisImage analysis may be visual, semiquantitative, or quantitative; visual interpretation is usually sufficient for symptomatic PD due to substantial loss of dopaminergic neurons.

Essential tremor (ET) definition

Core featuresIsolated bilateral upper-limb action tremor (kinetic and postural) lasting ≥3 years, with or without tremor elsewhere, and absence of other neurologic signs.

Diagnostic sourceBased on International Parkinson and Movement Disorder Society (IPMDS) task force criteria.

Exclusion of other signsDiagnosis requires absence of other motor abnormalities indicative of parkinsonism.

Parkinson disease (PD) clinical diagnostic criteria

Essential diagnostic requirementParkinsonism defined as bradykinesia plus either rest tremor or rigidity (essential criterion).

Supportive criteria examplesClear beneficial response to dopaminergic therapy, levodopa-induced dyskinesia, limb rest tremor, olfactory loss or cardiac sympathetic denervation.

Exclusions and red flagsDiagnosis requires absence of any absolute exclusion criteria and consideration of red flags per MDS guidance.

DAT‑SPECT shorthand definition

ShorthandDAT‑SPECT = dopamine transporter imaging using SPECT to assess presynaptic dopaminergic function.

PurposeDetects presynaptic dopaminergic deficit indicative of nigrostriatal degeneration.

Interpretation methodsVisual, semiquantitative, or quantitative analysis; visual interpretation is commonly used clinically.

Indicative biomarker (DLB) — reduced dopamine transporter uptake as an indicative biomarker

Indicative biomarker descriptionReduced dopamine transporter uptake in the basal ganglia on SPECT or PET is listed as an indicative biomarker for dementia with Lewy bodies (DLB).

Context of biomarker useUsed alongside clinical features (eg, fluctuating cognition, visual hallucinations, REM sleep behavior disorder) to support DLB diagnosis.

Imaging roleA positive (reduced uptake) DaT-SPECT can support distinction of DLB from Alzheimer disease.

DaT-SPECT general definition (duplicate variant)

General definitionDaT-SPECT is presynaptic dopaminergic imaging that detects loss of nigrostriatal dopamine transporter binding to support differential diagnosis of parkinsonian syndromes and DLB.

Diagnostic limitationsCannot reliably distinguish among different degenerative parkinsonian syndromes (eg, PD vs PSP vs MSA).

Clinical applicationsSupports differentiation between essential tremor and neurodegenerative parkinsonian syndromes and between presynaptic degenerative causes and drug-induced/psychogenic/vascular parkinsonism.

Postmortem neuropathologic exam as reference standard definition

Reference standard definitionPostmortem neuropathologic examination (autopsy-confirmed diagnosis) is the definitive reference standard for evaluating diagnostic accuracy of DaT-SPECT.

Evidence notesOnly a small number of studies have used postmortem neuropathologic reference standard (eg, Walker 2009; Thomas 2017).

Use in validity assessmentStudies with autopsy reference provide the most direct assessment of DaT-SPECT diagnostic accuracy for DLB/AD differentiation.

DaT-SPECT / 123I-FP-CIT (Ioflupane) SPECT definition

Test descriptionDaT-SPECT using 123I-FP-CIT (ioflupane, DaTscan) is a presynaptic dopaminergic imaging modality that detects loss of nigrostriatal dopamine transporter binding.

Regulatory noteDaTscan (123I-ioflupane) was FDA-approved in 2011 for suspected parkinsonian syndromes and approval expanded in 2022 for suspected DLB.

Clinical roleUsed to support differential diagnosis of ET vs parkinsonian tremor and to aid DLB vs AD differentiation as an adjunct to clinical evaluation.

Normal functional neuroimaging of presynaptic dopaminergic system — Movement Disorders Society exclusion criterion

MDS exclusion criterionNormal functional neuroimaging of the presynaptic dopaminergic system is listed by the Movement Disorders Society as an absolute exclusion criterion for PD diagnosis.

ImplicationA normal DaT-SPECT, when obtained, makes neurodegenerative parkinsonian syndromes highly unlikely and is therefore exclusionary.

LimitationsDaT imaging does not replace clinical diagnosis and does not distinguish PD from other degenerative parkinsonian disorders.

Short definition for DaT-SPECT

Short definitionDaT-SPECT: dopamine transporter imaging with SPECT to assess presynaptic dopaminergic deficit.

Image analysisCan be interpreted visually or with semiquantitative/quantitative methods; visual reading is often sufficient in symptomatic patients.

Clinical implicationAbnormal scan supports neurodegenerative parkinsonism; normal scan supports non-nigrostriatal causes.

DaT SPECT (I-123 FP-CIT, DaTscan) explicit definition

Explicit definitionDaT SPECT (I-123 FP-CIT, DaTscan) is a nuclear medicine SPECT imaging technique using I-123 labeled FP-CIT to assess presynaptic dopamine transporter binding in the striatum, indicating integrity of nigrostriatal dopaminergic neurons.

Clinical useUsed after neurologist assessment as an adjunct to differentiate neurodegenerative parkinsonian syndromes from non-neurodegenerative causes and to aid DLB vs AD distinction.

Safety/evidence noteSafety analyses and long-term follow-up data exist for ioflupane; use should be limited to appropriate clinical contexts.

Clinically uncertain DLB definition

Clinically uncertain DLB definitionPatients with dementia whose clinical features overlap between dementia with Lewy bodies and other dementias (eg, Alzheimer disease), or who have only some suggestive/core features such that diagnosis remains uncertain and imaging would affect management.

When imaging is usefulDaT-SPECT is useful when a positive (reduced uptake) result would inform management, particularly to avoid neuroleptic use.

Reference contextDLB diagnostic framework includes indicative biomarkers such as reduced striatal DaT uptake on SPECT or PET.

Imaging modality description — presynaptic DAT visualization

Modality descriptionImaging modality that visualizes presynaptic dopamine transporter to assess nigrostriatal dopaminergic degeneration using SPECT and specific radiotracers.

Functional assessmentPermits assessment of presynaptic dopaminergic deficit to support differentiation of degenerative vs non-degenerative causes of parkinsonism.

Analytic approachesVisual, semiquantitative, and quantitative methods are used; sites may establish reference ranges for semiquantitative analysis.

Clinical diagnosis by specialist at 3-5 years follow-up as reference standard

Reference standard used in practice/evidenceClinical diagnosis by a Parkinson disease and movement disorder specialist at 3–5 years follow-up is used as a practical reference standard for evaluating DaT-SPECT diagnostic performance.

RationaleSupported by meta-analytic comparisons of clinical diagnosis with pathologic findings and used in diagnostic performance studies where autopsy is unavailable.

Implication for studiesLongitudinal specialist follow-up provides a clinically meaningful comparator when postmortem confirmation is not feasible.

Policy effective date recorded as February 2019 in the document metadata.

Policy history reflects annual reviews and revisions through 2019–2025; providers should verify the current policy/version with the payer prior to authorization.